RB1 (P06400) variants and mutations
RB1 (also known as P06400) is a human protein-coding gene encoding a retinoblastoma-associated protein. It restrains E2F-dependent transcription and prevents inappropriate G1-to-S cell-cycle progression until proliferative signals are appropriate. Loss of function is a fundamental cancer-driving event, while germline pathogenic variants cause hereditary retinoblastoma and increase risk of additional tumors. This analysis covers 3,857 RB1 variants and mutations. Of these, 44% have computational variant effect predictions. Disease context includes retinoblastoma, hereditary retinoblastoma, and urinary bladder cancer. Example RB1 variants include M1L, P2A, and P2L.
Variant analysis overview
- Gene: RB1
- Protein: P06400
- UniProt accession: P06400
- Organism: Homo sapiens
- Variants analyzed: 3857
- Variant scope: all variants
- Completed: 2026-08-10
Variant and mutation evidence
- Variant composition: 3,696 unspecified-consequence records; 69 missense variants; 72 synonymous variants; 6 frameshift variants; 6 in-frame deletions; 3 in-frame insertions; 2 stop-gained variants; 2 splice-region variants; 1 stop lost
- Prediction scores: 1,699 variants have prediction scores (44% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: retinoblastoma, hereditary retinoblastoma, urinary bladder cancer, urinary bladder carcinoma, small cell lung carcinoma, non-hereditary retinoblastoma, hepatocellular carcinoma, lung adenocarcinoma, trilateral retinoblastoma, osteosarcoma, cancer, bone osteosarcoma.
Protein structure and variant hotspots
- Protein features: 24 post-translational modification sites.
- PTM context: 88 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable RB1 variants
Examples include M1L, P2A, P2L, P2S, P2T, P2Q, P2P, P3A. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1L (p.Met1Leu), rs2138026940, ClinGen CA388250130, ClinVar RCV001964943, MetaLR 0.66, MetaSVM 0.28, Uncertain significance, Hereditary cancer-predisposing syndrome
- P2A (p.Pro2Ala), gnomAD rs1328198608, REVEL 0.64, MetaLR 0.79, Uncertain significance
- P2L (p.Pro2Leu), Ensembl rs2138026976, REVEL 0.61, MetaLR 0.77
- P2S (p.Pro2Ser), cosmic curated COSV57321, gnomAD rs1328198608, REVEL 0.64, MetaLR 0.79, Uncertain significance
- P2T (p.Pro2Thr), rs1328198608, ClinGen CA388250137, ClinVar RCV001229314, gnomAD rs1328198608, REVEL 0.64, MetaLR 0.79, Uncertain significance, Retinoblastoma
- P2Q (p.Pro2Gln), gnomAD 13-48303917-C-A, REVEL 0.57, MetaLR 0.81
- P2P (p.Pro2Pro), rs1593411898, gnomAD 13-48303918-G-T, CADD 15.30
- P3A (p.Pro3Ala), rs2138026983, ClinGen CA388250144, ClinVar RCV004525320, ClinVar RCV005100727, AlphaMissense 0.11, MetaLR 0.79, Uncertain significance, Retinoblastoma; Hereditary cancer-predisposing syndrome
- P3H (p.Pro3His), Ensembl rs2138026992, REVEL 0.60, MetaLR 0.82
- P3L (p.Pro3Leu), rs2138026992, ClinGen CA388250148, ClinVar RCV003471812, ClinVar RCV003779096, REVEL 0.66, MetaLR 0.79, Uncertain significance, Malignant tumor of urinary bladder; Retinoblastoma; Hereditary cancer-predisposi
- P3S (p.Pro3Ser), rs2138026983, ClinGen CA388250145, ClinVar RCV004525321, AlphaMissense 0.11, MetaLR 0.79, Uncertain significance, Hereditary cancer-predisposing syndrome
- P3T (p.Pro3Thr), gnomAD 13-48303919-C-A, REVEL 0.62, MetaLR 0.79
- P3P (p.Pro3Pro), rs2138026999, gnomAD 13-48303921-C-A, CADD 15.30
- K4E (p.Lys4Glu), rs2542093127, ClinGen CA2697551896, ClinVar RCV003514661, REVEL 0.56, MetaLR 0.76, Uncertain significance, Retinoblastoma
- K4I (p.Lys4Ile), TOPMed rs1371181708, gnomAD rs1371181708, Uncertain significance
- K4N (p.Lys4Asn), Ensembl rs2138027015, REVEL 0.41, MetaLR 0.80
- K4R (p.Lys4Arg), rs1371181708, ClinGen CA388250154, ClinVar RCV001057690, TOPMed rs1371181708, REVEL 0.42, MetaLR 0.76, Uncertain significance, Retinoblastoma
- K4Q (p.Lys4Gln), gnomAD 13-48303922-A-C, REVEL 0.47, MetaLR 0.80
- T5A (p.Thr5Ala), rs898303682, ClinGen CA388250157, ClinVar RCV001067348, ClinVar RCV002393325, REVEL 0.20, MetaLR 0.30, Uncertain significance, Retinoblastoma; Hereditary cancer-predisposing syndrome
- T5I (p.Thr5Ile), rs1265159988, ClinGen CA388250161, ClinVar RCV000809422, ClinVar RCV002390624, REVEL 0.10, MetaLR 0.50, Uncertain significance, Hereditary cancer-predisposing syndrome; Retinoblastoma
- T5N (p.Thr5Asn), NCI-TCGA TCGA novel, cosmic curated COSV57333, 1000Genomes rs1265159988, gnomAD rs1265159988, REVEL 0.08, MetaLR 0.50, Uncertain significance, Hereditary cancer-predisposing syndrome
- T5P (p.Thr5Pro), rs898303682, ClinGen CA249842021, ClinVar RCV000632954, ClinVar RCV003321697, REVEL 0.13, MetaLR 0.45, Uncertain significance, not specified; Retinoblastoma; Hereditary cancer-predisposing syndrome
- T5S (p.Thr5Ser), 1000Genomes rs1265159988, gnomAD rs1265159988, REVEL 0.17, MetaLR 0.34, Uncertain significance, Retinoblastoma; Hereditary cancer-predisposing syndrome
- P6H (p.Pro6His), rs755482658, ClinGen CA388250164, ClinVar RCV001891978, ExAC rs755482658, AlphaMissense 0.19, MetaLR 0.66, Uncertain significance, Retinoblastoma
- P6L (p.Pro6Leu), rs755482658, ClinGen CA032568, ClinVar RCV002407875, ClinVar RCV003626773, REVEL 0.22, AlphaMissense 0.19, Conflicting interpretations, Malignant tumor of urinary bladder; Hereditary cancer-predisposing syndrome; Ret
- P6S (p.Pro6Ser), rs886043138, ClinGen CA10605156, cosmic curated COSV57323, ClinVar RCV000382603, REVEL 0.14, MetaLR 0.52, Conflicting interpretations, Hereditary cancer-predisposing syndrome; not provided; Retinoblastoma
- P6T (p.Pro6Thr), TOPMed rs886043138, gnomAD rs886043138, REVEL 0.14, MetaLR 0.56, Benign
- P6P (p.Pro6Pro), rs1017683562, gnomAD 13-48303930-C-T, CADD 14.20
- R7* (p.Arg7Ter), cosmic curated COSV99924, TOPMed rs1952051704, CADD 35.00, Likely benign
- R7G (p.Arg7Gly), TOPMed rs1952051704, REVEL 0.41, MetaLR 0.79, Uncertain significance, Hereditary cancer-predisposing syndrome
- R7Q (p.Arg7Gln), rs564059250, ClinGen CA249842023, cosmic curated COSV57301, ClinVar RCV001207424, REVEL 0.32, MetaLR 0.80, Uncertain significance, Hereditary cancer-predisposing syndrome; Retinoblastoma
- R7E (p.Arg7Glu), rs1131690852, gnomAD 13-48303925-AC-A, CADD 22.50
- R7P (p.Arg7Pro), rs1131690852, gnomAD 13-48303925-A-AC, CADD 23.90
- R7R (p.Arg7Arg), rs1952051704, gnomAD 13-48303931-C-A, CADD 12.50
- R7L (p.Arg7Leu), gnomAD 13-48303932-G-T, REVEL 0.47, MetaLR 0.78
- K8* (p.Lys8Ter), rs2542093262, ClinGen CA2697551897, ClinVar RCV003514161, Pathogenic
- K8E (p.Lys8Glu), rs2542093267, ClinGen CA388250170, ClinVar RCV003017520, ClinVar RCV003340592, REVEL 0.17, MetaLR 0.59, Uncertain significance, Hereditary cancer-predisposing syndrome; Retinoblastoma
- K8N (p.Lys8Asn), rs2138027103, ClinGen CA388250176, ClinVar RCV002431063, ClinVar RCV004007432, REVEL 0.19, MetaLR 0.59, Uncertain significance, Hereditary cancer-predisposing syndrome; Retinoblastoma
- K8Q (p.Lys8Gln), gnomAD 13-48303934-A-C, REVEL 0.14, MetaLR 0.59
- K8K (p.Lys8Lys), gnomAD 13-48303936-A-G, CADD 13.20
- T9A (p.Thr9Ala), Ensembl rs2138027109, Uncertain significance, Retinoblastoma
- T9M (p.Thr9Met), rs1952051803, ClinGen CA388250183, ClinVar RCV001317389, ClinVar RCV005470740, REVEL 0.07, MetaLR 0.51, Uncertain significance, Hereditary cancer-predisposing syndrome; Retinoblastoma
- T9N (p.Thr9Asn), rs2542093245, ClinVar RCV004557029, Pathogenic
- T9P (p.Thr9Pro), rs2138027109, ClinGen CA388250178, ClinVar RCV004017156, Ensembl rs2138027109, REVEL 0.17, MetaLR 0.40, Uncertain significance, Retinoblastoma
- T9R (p.Thr9Arg), rs1952051803, ClinGen CA388250182, ClinVar RCV001351756, Ensembl rs1952051803, REVEL 0.09, MetaLR 0.47, Uncertain significance, Retinoblastoma
- T9K (p.Thr9Lys), gnomAD 13-48303938-C-A, REVEL 0.12, MetaLR 0.46
- T9T (p.Thr9Thr), gnomAD 13-48303939-G-T, CADD 9.22
- A10P (p.Ala10Pro), Ensembl rs1593411967
- A10T (p.Ala10Thr), rs1593411967, ClinGen CA388250184, ClinVar RCV003515664, REVEL 0.11, MetaLR 0.59, Uncertain significance, Retinoblastoma
- A10V (p.Ala10Val), Ensembl rs2138027139, REVEL 0.07, MetaLR 0.57, Uncertain significance, Hereditary cancer-predisposing syndrome
- A10D (p.Ala10Asp), gnomAD 13-48303941-C-A, REVEL 0.24, MetaLR 0.60
- A10A (p.Ala10Ala), rs530961288, gnomAD 13-48303942-C-T, CADD 9.76
- A11G (p.Ala11Gly), rs899323337, ClinGen CA249842025, ClinVar RCV000632957, ClinVar RCV002325216, REVEL 0.08, MetaLR 0.50, Uncertain significance, Retinoblastoma; Hereditary cancer-predisposing syndrome
- A11P (p.Ala11Pro), Ensembl rs587778852, Uncertain significance
- A11S (p.Ala11Ser), rs587778852, ClinGen CA026450, ClinVar RCV000114708, Ensembl rs587778852, REVEL 0.06, MetaLR 0.46, Uncertain significance, Retinoblastoma
- A11T (p.Ala11Thr), rs587778852, ClinGen CA388250191, cosmic curated COSV57295, ClinVar RCV004012320, REVEL 0.08, MetaLR 0.48, Uncertain significance, Retinoblastoma; Hereditary cancer-predisposing syndrome
- A11V (p.Ala11Val), rs899323337, ClinGen CA388250193, ClinVar RCV002326210, ClinVar RCV003099379, REVEL 0.11, MetaLR 0.48, Uncertain significance, Hereditary cancer-predisposing syndrome; Retinoblastoma
- A11D (p.Ala11Asp), gnomAD 13-48303944-C-A, REVEL 0.13, MetaLR 0.55
- A11A (p.Ala11Ala), rs1593411999, gnomAD 13-48303945-C-T, CADD 6.94
- T12A (p.Thr12Ala), rs1566174063, ClinGen CA388250195, ClinVar RCV000822727, ClinVar RCV005260447, REVEL 0.17, MetaLR 0.38, Conflicting interpretations, Hereditary cancer-predisposing syndrome; Retinoblastoma
- T12I (p.Thr12Ile), Ensembl rs2138027197, REVEL 0.11, MetaLR 0.49
- T12S (p.Thr12Ser), rs1566174063, ClinGen CA388250196, ClinVar RCV000703761, ClinVar RCV001020458, REVEL 0.12, MetaLR 0.47, Likely benign, Hereditary cancer-predisposing syndrome; Retinoblastoma
- p.Thr12 Ala17del, rs1481932082, gnomAD 13-48303937-ACGGC, CADD 15.70
- p.Thr12dup, rs1471810016, gnomAD 13-48303943-G-GCC, CADD 13.70
- T12N (p.Thr12Asn), gnomAD 13-48303947-C-A, REVEL 0.13, MetaLR 0.49
- T12T (p.Thr12Thr), gnomAD 13-48303948-C-A, CADD 5.04
- A13D (p.Ala13Asp), Ensembl rs2138027251, REVEL 0.11, MetaLR 0.49, Uncertain significance, Hereditary cancer-predisposing syndrome
- A13G (p.Ala13Gly), rs2138027251, ClinGen CA388250204, ClinVar RCV002357454, REVEL 0.08, MetaLR 0.50, Uncertain significance, Hereditary cancer-predisposing syndrome
- A13P (p.Ala13Pro), Ensembl rs2138027234
- A13T (p.Ala13Thr), Ensembl rs2138027234, REVEL 0.10, MetaLR 0.46
- A13V (p.Ala13Val), rs2138027251, ClinGen CA388250205, ClinVar RCV003514680, REVEL 0.12, MetaLR 0.51, Uncertain significance, Retinoblastoma
- A13S (p.Ala13Ser), gnomAD 13-48303949-G-T, REVEL 0.08, MetaLR 0.50
- A13A (p.Ala13Ala), gnomAD 13-48303951-C-A, CADD 4.01
- A14L (p.Ala14Leu), rs2542093473, ClinGen CA2580087718, ClinVar RCV003171434, ClinVar RCV006473828, Uncertain significance, Retinoblastoma; Hereditary cancer-predisposing syndrome
- A14P (p.Ala14Pro), Ensembl rs2138027266, REVEL 0.16, MetaLR 0.45
- A14T (p.Ala14Thr), cosmic curated COSV10940, Ensembl rs2138027266, REVEL 0.16, MetaLR 0.46
- A14V (p.Ala14Val), Ensembl rs1952052497, REVEL 0.14, MetaLR 0.54, Uncertain significance, Retinoblastoma
- A14S (p.Ala14Ser), gnomAD 13-48303952-G-T, REVEL 0.12, MetaLR 0.47
- A14D (p.Ala14Asp), gnomAD 13-48303953-C-A, REVEL 0.22, MetaLR 0.55
- A14A (p.Ala14Ala), gnomAD 13-48303954-C-A, CADD 6.23
- A15G (p.Ala15Gly), rs564137727, ClinGen CA249842026, ClinVar RCV000693012, 1000Genomes rs564137727, REVEL 0.11, MetaLR 0.55, Uncertain significance, Retinoblastoma
- A15P (p.Ala15Pro), rs587778638, ClinGen CA026457, ClinVar RCV000121916, ClinVar RCV004658972, AlphaMissense 0.14, MetaLR 0.52, Uncertain significance, Hereditary cancer-predisposing syndrome
- A15S (p.Ala15Ser), Ensembl rs587778638, REVEL 0.17, AlphaMissense 0.14, Uncertain significance
- A15T (p.Ala15Thr), cosmic curated COSV57297, Ensembl rs587778638, REVEL 0.17, AlphaMissense 0.14, Uncertain significance, Retinoblastoma
- A15V (p.Ala15Val), 1000Genomes rs564137727, REVEL 0.14, MetaLR 0.55, Uncertain significance
- A15A (p.Ala15Ala), rs1593412047, gnomAD 13-48303957-T-C, CADD 4.96
- A16V (p.Ala16Val), Ensembl rs2138027357, REVEL 0.14, MetaLR 0.49
- A16P (p.Ala16Pro), Ensembl rs2138027331
- A16T (p.Ala16Thr), Ensembl rs2138027331, REVEL 0.14, MetaLR 0.47
- p.Ala16 Ala18del, rs572454921, gnomAD 13-48303948-CGCCG, CADD 11.80
- A16S (p.Ala16Ser), gnomAD 13-48303958-G-T, REVEL 0.17, MetaLR 0.41
- A16D (p.Ala16Asp), gnomAD 13-48303959-C-A, REVEL 0.18, MetaLR 0.50
- A16A (p.Ala16Ala), gnomAD 13-48303960-C-G, CADD 6.38
- A17P (p.Ala17Pro), Ensembl rs1566174092, Uncertain significance
- A17S (p.Ala17Ser), rs1566174092, ClinGen CA388250224, ClinVar RCV002343022, ClinVar RCV006559031, REVEL 0.13, MetaLR 0.51, Uncertain significance, Hereditary cancer-predisposing syndrome; Retinoblastoma
- A17T (p.Ala17Thr), rs1566174092, ClinGen CA388250222, ClinVar RCV001294674, ClinVar RCV002339719, REVEL 0.09, MetaLR 0.45, Uncertain significance, Hereditary cancer-predisposing syndrome; Retinoblastoma
- A17V (p.Ala17Val), rs1593412070, ClinGen CA388250226, ClinVar RCV001023539, ClinVar RCV001862264, REVEL 0.11, MetaLR 0.56, Uncertain significance, Hereditary cancer-predisposing syndrome; Retinoblastoma
- p.Ala17 Ala18del, gnomAD 13-48303957-TGCCG, CADD 14.10
- A17D (p.Ala17Asp), gnomAD 13-48303962-C-A, REVEL 0.15, MetaLR 0.54
- A17A (p.Ala17Ala), rs1593412073, gnomAD 13-48303963-C-G, CADD 8.37
- A18T (p.Ala18Thr), rs528218090, ClinGen CA388250228, cosmic curated COSV57307, ClinVar RCV000802787, REVEL 0.13, MetaLR 0.54, Uncertain significance, Retinoblastoma
- A18P (p.Ala18Pro), 1000Genomes rs528218090, ExAC rs528218090, TOPMed rs528218090, gnomAD rs528218090, Benign
- A18S (p.Ala18Ser), rs528218090, ClinGen CA038529, ClinVar RCV000226647, ClinVar RCV000568995, REVEL 0.14, MetaLR 0.54, Benign/Likely benign, Hereditary cancer-predisposing syndrome; Hereditary retinoblastoma; Retinoblasto
- A18del (p.Ala18del), gnomAD 13-48303946-ACCG-, CADD 9.71
- A18E (p.Ala18Glu), gnomAD 13-48303965-C-A, REVEL 0.16, MetaLR 0.49
- A18V (p.Ala18Val), gnomAD 13-48303965-C-T, REVEL 0.19, MetaLR 0.49
- A18A (p.Ala18Ala), rs2138027406, gnomAD 13-48303966-G-A, CADD 8.89
- E19* (p.Glu19Ter), rs2138027419, ClinGen CA388250235, ClinVar RCV002344894, ClinVar RCV004556852, CADD 35.00, Pathogenic
- E19A (p.Glu19Ala), Ensembl rs2138027431, Uncertain significance
- E19D (p.Glu19Asp), Ensembl rs1046808421
- E19G (p.Glu19Gly), Ensembl rs2138027431, Uncertain significance, Hereditary cancer-predisposing syndrome
- E19K (p.Glu19Lys), Ensembl rs2138027419, REVEL 0.26, MetaLR 0.65
- E19P (p.Glu19Pro), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- E19Q (p.Glu19Gln), Ensembl rs2138027419
- E19V (p.Glu19Val), rs2138027431, ClinGen CA388250237, ClinVar RCV002302149, AlphaMissense 0.06, MetaLR 0.64, Uncertain significance, Retinoblastoma
- E19E (p.Glu19Glu), gnomAD 13-48303969-A-G, CADD 8.29
- P20L (p.Pro20Leu), rs587778637, ClinGen CA026462, cosmic curated COSV10585, ClinVar RCV000121915, REVEL 0.63, MetaLR 0.66, Conflicting interpretations, not specified; not provided; Hereditary cancer-predisposing syndrome
- P20S (p.Pro20Ser), rs1297224382, ClinGen CA388250242, ClinVar RCV002355688, ClinVar RCV004005711, REVEL 0.29, MetaLR 0.66, Uncertain significance, Hereditary cancer-predisposing syndrome; Retinoblastoma
- P20T (p.Pro20Thr), TOPMed rs1297224382, gnomAD rs1297224382, REVEL 0.33, MetaLR 0.66, Uncertain significance, Retinoblastoma; Hereditary cancer-predisposing syndrome
- P20H (p.Pro20His), gnomAD 13-48303971-C-A, REVEL 0.33, MetaLR 0.66
- P20P (p.Pro20Pro), rs777340111, gnomAD 13-48303972-C-G, CADD 10.40
- P21L (p.Pro21Leu), rs1444353743, ClinGen CA388250249, ClinVar RCV000698668, ClinVar RCV002360783, REVEL 0.26, MetaLR 0.65, Conflicting interpretations, Retinoblastoma; Malignant tumor of urinary bladder; Hereditary cancer-predisposi
- P21Q (p.Pro21Gln), TOPMed rs1444353743, gnomAD rs1444353743, Likely benign
- P21R (p.Pro21Arg), rs1469887040, ClinGen CA609859321, ClinVar RCV003301741, ClinVar RCV006472278, REVEL 0.22, MetaLR 0.60, Uncertain significance, Hereditary cancer-predisposing syndrome; Retinoblastoma
- P21S (p.Pro21Ser), Ensembl rs2138027484
- P21T (p.Pro21Thr), gnomAD 13-48303973-C-A, REVEL 0.25, MetaLR 0.62
- P21A (p.Pro21Ala), gnomAD 13-48303973-C-G, REVEL 0.20, MetaLR 0.56
- P21P (p.Pro21Pro), rs1313614748, gnomAD 13-48303975-G-A, CADD 5.83
- A22E (p.Ala22Glu), Ensembl rs2138027521, REVEL 0.06, MetaLR 0.12, Uncertain significance, Retinoblastoma
- A22G (p.Ala22Gly), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- A22T (p.Ala22Thr), Ensembl rs2138027513, REVEL 0.09, MetaLR 0.13, Likely benign, Hereditary cancer-predisposing syndrome
- A22V (p.Ala22Val), Ensembl rs2138027521, REVEL 0.06, MetaLR 0.14
- A22S (p.Ala22Ser), gnomAD 13-48303976-G-T, REVEL 0.10, MetaLR 0.11
- A22A (p.Ala22Ala), rs1014225642, gnomAD 13-48303978-A-C, CADD 5.74
- P23L (p.Pro23Leu), rs1952053594, ClinGen CA388250261, cosmic curated COSV10875, ClinVar RCV001940507, REVEL 0.24, AlphaMissense 0.11, Uncertain significance, Hereditary cancer-predisposing syndrome; Retinoblastoma
- P23Q (p.Pro23Gln), rs1952053594, ClinGen CA388250262, ClinVar RCV001048894, Ensembl rs1952053594, REVEL 0.23, AlphaMissense 0.11, Uncertain significance, Retinoblastoma
- P23R (p.Pro23Arg), rs1952053594, ClinGen CA388250260, ClinVar RCV002362317, AlphaMissense 0.11, MetaLR 0.42, Uncertain significance, Hereditary cancer-predisposing syndrome
- P23S (p.Pro23Ser), rs1349657979, ClinGen CA388250258, ClinVar RCV001036984, ClinVar RCV004818195, REVEL 0.25, MetaLR 0.49, Uncertain significance, Hereditary cancer-predisposing syndrome; Retinoblastoma
- P23T (p.Pro23Thr), rs1349657979, ClinGen CA388250259, ClinVar RCV001220684, ClinVar RCV005722328, REVEL 0.26, MetaLR 0.47, Uncertain significance, Hereditary cancer-predisposing syndrome; Retinoblastoma
- P23A (p.Pro23Ala), gnomAD 13-48303979-C-G, REVEL 0.18, MetaLR 0.43
- P23P (p.Pro23Pro), rs746662122, gnomAD 13-48303981-G-A, CADD 7.07
- P24L (p.Pro24Leu), rs1285455572, ClinGen CA388250268, ClinVar RCV001340818, ClinVar RCV004035952, REVEL 0.30, MetaLR 0.69, Uncertain significance, Hereditary cancer-predisposing syndrome; Retinoblastoma
- P24Q (p.Pro24Gln), rs1285455572, ClinGen CA388250266, ClinVar RCV002370838, REVEL 0.29, MetaLR 0.69, Uncertain significance, Hereditary cancer-predisposing syndrome
- P24S (p.Pro24Ser), TOPMed rs1952053688, gnomAD rs1952053688, REVEL 0.26, MetaLR 0.65, Uncertain significance, Retinoblastoma
- P24T (p.Pro24Thr), TOPMed rs1952053688, gnomAD rs1952053688, REVEL 0.30, MetaLR 0.69
- P24A (p.Pro24Ala), gnomAD 13-48303982-C-G, REVEL 0.26, MetaLR 0.68
- P24R (p.Pro24Arg), gnomAD 13-48303983-C-G, REVEL 0.27, MetaLR 0.66
- P24P (p.Pro24Pro), gnomAD 13-48303984-G-T, CADD 6.93
- P25L (p.Pro25Leu), rs1593412158, ClinGen CA388250274, ClinVar RCV001026505, ClinVar RCV001862369, REVEL 0.22, MetaLR 0.49, Conflicting interpretations, Retinoblastoma; Hereditary cancer-predisposing syndrome
- P25R (p.Pro25Arg), Ensembl rs1593412158, REVEL 0.13, MetaLR 0.47, Uncertain significance
- P25S (p.Pro25Ser), rs1566174119, ClinGen CA388250271, ClinVar RCV001946175, Ensembl rs1566174119, REVEL 0.23, MetaLR 0.42, Uncertain significance, Retinoblastoma
- P25T (p.Pro25Thr), rs1566174119, ClinGen CA388250269, ClinVar RCV002811374, REVEL 0.20, MetaLR 0.46, Uncertain significance, Retinoblastoma
- P25Q (p.Pro25Gln), gnomAD 13-48303986-C-A, REVEL 0.12, MetaLR 0.50
- P25P (p.Pro25Pro), rs2138027609, gnomAD 13-48303987-G-T, CADD 6.39
- P26A (p.Pro26Ala), Ensembl rs2138027626, Uncertain significance, Hereditary cancer-predisposing syndrome; Retinoblastoma
- P26L (p.Pro26Leu), ExAC rs770488256, gnomAD rs770488256, REVEL 0.33, MetaLR 0.35, Uncertain significance, Hereditary cancer-predisposing syndrome
- P26N (p.Pro26Asn), rs2542093681, ClinGen CA2580087723, ClinVar RCV003176998, Pathogenic
- P26S (p.Pro26Ser), rs2138027626, ClinGen CA388250275, ClinVar RCV002400583, ClinVar RCV003099720, REVEL 0.25, MetaLR 0.31, Uncertain significance, Hereditary cancer-predisposing syndrome; Retinoblastoma
- P26T (p.Pro26Thr), gnomAD 13-48303988-C-A, REVEL 0.22, MetaLR 0.39
- P26Q (p.Pro26Gln), gnomAD 13-48303989-C-A, REVEL 0.18, MetaLR 0.31
- P26P (p.Pro26Pro), rs1389899415, gnomAD 13-48303990-G-C, CADD 6.19
- P27A (p.Pro27Ala), gnomAD rs1309325353, Uncertain significance
- P27H (p.Pro27His), TOPMed rs925399787, gnomAD rs925399787, REVEL 0.35, MetaLR 0.50, Uncertain significance
- P27L (p.Pro27Leu), rs925399787, ClinGen CA388250284, ClinVar RCV003626333, REVEL 0.33, MetaLR 0.49, Uncertain significance, Retinoblastoma
- P27R (p.Pro27Arg), rs925399787, ClinGen CA249842029, ClinVar RCV001213879, ClinVar RCV002256701, REVEL 0.23, MetaLR 0.49, Conflicting interpretations, Hereditary cancer-predisposing syndrome; Retinoblastoma
- P27S (p.Pro27Ser), rs1309325353, ClinGen CA388250282, ClinVar RCV001374201, ClinVar RCV002420848, REVEL 0.26, MetaLR 0.35, Uncertain significance, Hereditary cancer-predisposing syndrome; Retinoblastoma
- P27P (p.Pro27Pro), rs1555279227, gnomAD 13-48303993-C-A, CADD 1.83
- P28H (p.Pro28His), 1000Genomes rs776175164, ExAC rs776175164, TOPMed rs776175164, gnomAD rs776175164, REVEL 0.37, MetaLR 0.49, Uncertain significance, not provided
- P28L (p.Pro28Leu), rs776175164, ClinGen CA388250287, ClinVar RCV000688608, ClinVar RCV002440436, REVEL 0.32, MetaLR 0.44, Conflicting interpretations, Retinoblastoma; not provided; Hereditary cancer-predisposing syndrome
- P28R (p.Pro28Arg), rs776175164, ClinGen CA039558, cosmic curated COSV99923, ClinVar RCV000470650, REVEL 0.23, MetaLR 0.45, Conflicting interpretations, Retinoblastoma; Hereditary cancer-predisposing syndrome
- P28S (p.Pro28Ser), rs1020342293, ClinGen CA249842030, ClinVar RCV003844847, TOPMed rs1020342293, REVEL 0.13, MetaLR 0.38, Uncertain significance, Retinoblastoma
- P28T (p.Pro28Thr), rs1020342293, ClinGen CA388250285, ClinVar RCV003338957, TOPMed rs1020342293, REVEL 0.12, MetaLR 0.46, Uncertain significance, Hereditary cancer-predisposing syndrome
- P28P (p.Pro28Pro), gnomAD 13-48303996-T-C, CADD 12.00
- P29R (p.Pro29Arg), TOPMed rs938094455, gnomAD rs938094455, Uncertain significance
- P29A (p.Pro29Ala), Ensembl rs2138027701
- P29L (p.Pro29Leu), rs938094455, ClinGen CA249842031, ClinVar RCV001068419, ClinVar RCV002374984, REVEL 0.18, MetaLR 0.47, Uncertain significance, Hereditary cancer-predisposing syndrome; Retinoblastoma
- P29del (p.Pro29del), rs1298675805, gnomAD 13-48303976-GCAC-, CADD 12.70
- p.Pro29dup, rs587778823, gnomAD 13-48303978-A-ACC, CADD 13.10
- P29S (p.Pro29Ser), gnomAD 13-48303990-G-GC, CADD 16.90
- P29T (p.Pro29Thr), gnomAD 13-48303997-C-A, REVEL 0.14, MetaLR 0.46
Public RB1 analysis runs
- RB1 analysis run — RB1 (3,857 variants) — completed 2026-08-10